错配修复缺陷转移性结直肠癌的免疫治疗——结局与新型预测标志物
本研究基于MD安德森癌症中心和Sheba医疗中心两个前瞻性队列,纳入2014至2022年间接受免疫治疗的153例错配修复缺陷/高度微卫星不稳定转移性结直肠癌患者,评估疗效预测标志物。中位随访26个月,中位无进展生存期51.6个月,客观缓解率58.1%。单因素分析显示男性、肝或肺转移、ECOG-PS评分≥2、治疗前CEA>5 μg/L及≥3个转移部位与更差的无进展生存期相关,右半肿瘤与更好无进展生存期相关;肝或肺转移在多因素模型中仍显著。
要点
- 中位无进展生存期51.6个月(95%CI 38.1-未达到),客观缓解率58.1%。
- 肝转移HR 2.35、肺转移HR 2.30,均与更差的无进展生存期相关,多因素模型仍显著。
- ECOG-PS≥2、CEA>5 μg/L、≥3个转移部位及男性与更差的无进展生存期相关。
核心结论
- 疾病范围(高CEA、ECOG-PS差和≥3个转移部位与更差的无进展生存期相关)和疾病位置(肝或肺转移及左半肿瘤与更差的无进展生存期相关)与dMMR/MSI-H转移性结直肠癌的免疫治疗结局相关。
研究设计与样本
- 研究使用MD安德森癌症中心和Sheba医疗中心的两个前瞻性队列,纳入2014至2022年间接受免疫治疗的连续dMMR/MSI-H转移性结直肠癌患者,共153例。
- 主要终点为无进展生存期,次要终点为客观缓解率;评估的预测因素包括ECOG-PS评分、RAS/BRAF状态、单药与双药免疫治疗、转移部位、疾病负荷及治疗前CEA水平。
- 采用Kaplan-Meier分析和Cox比例风险回归模型分析暴露变量对无进展生存期的影响。
主要发现
- 中位随访时间26个月(IQR 11-48),中位无进展生存期51.6个月(95%CI 38.1-未达到),客观缓解率58.1%。
- 单因素分析中,男性与更差的无进展生存期相关,HR为1.67(95%CI 1.00-2.79);右半肿瘤与改善的无进展生存期相关,HR为0.56(95%CI 0.32-0.97)。
- 肝转移和肺转移分别与更差的无进展生存期相关,HR分别为2.35(95%CI 1.43-3.88)和2.30(95%CI 1.31-4.04)。
- ECOG-PS评分≥2、治疗前CEA水平>5 μg/L和≥3个转移部位分别与更差的无进展生存期相关,HR分别为2.09(95%CI 0.98-4.47)、2.23(95%CI 1.30-3.81)和3.11(95%CI 1.61-6.03)。
- 肝或肺转移在多因素模型中仍显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aims to assess predictive markers for response to immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) patients. MATERIALS AND METHODS: A study using two prospective cohorts from MD Anderson Cancer Center and Sheba Medical Center of consecutive patients with dMMR/MSI-H mCRC that were treated with immunotherapy between 2014-2022. Primary outcome was progression-free survival (PFS) and secondary outcome was overall response rate (ORR). Evaluated predictors included ECOG-PS score, RAS/BRAF status, single-agent versus doublet immunotherapy, metastatic sites, disease burden, and CEA levels prior to treatment initiation. Kaplan-Meier analysis and Cox proportional hazard regression model were used to analyze the effect of exposure variables on PFS. RESULTS: The study included 153 patients. Median follow-up time was 26 months (IQR 11-48). Median PFS was 51.6 months (95%CI 38.1-NR) and ORR was 58.1%. In a univariate analysis, male sex was associated with worse PFS with a HR of 1.67 (95% CI 1.00-2.79); Right-sided tumors were associated with improved PFS with a HR of 0.56 (95% CI 0.32-0.97); Liver or lung metastasis were associated with worse PFS with HRs of 2.35 (95%CI 1.43-3.88) and 2.30 (95%CI 1.31-4.04), respectively; ECOG-PS score ≥ 2, CEA levels ˃5 μg/L prior to treatment initiation and ≥ 3 metastatic sites were associated with worse PFS with HRs of 2.09 (95%CI 0.98-4.47), 2.23 (95%CI 1.30-3.81) and 3.11 (95%CI 1.61-6.03), respectively. Liver or lung metastasis remained significant in a multivariable model. CONCLUSIONS: Extent of disease (worse PFS with high CEA, poor ECOG-PS and ≥3 metastatic sites) and disease location (worse PFS with liver or lung metastasis and left sided tumor) were associated with immunotherapy outcome in dMMR/MSI-H mCRC.
引用
- Stemmer A, Margalit O, Serpas V, et al. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer. 2023. PMID: 38157568. doi:10.1016/j.ejca.2023.113495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。